FLOW CYTOMETRY, CD 117

The Flow Cytometry CD117 Test is a specialized laboratory investigation that evaluates the expression of CD117 (KIT) on the surface of cells using advanced flow cytometry technology. CD117 is a transmembrane receptor protein, also known as the KIT receptor, which plays an important role in the growth, survival, and development of hematopoietic stem cells and various other cell types.

CD117 is normally expressed on early bone marrow progenitor cells, mast cells, and certain other tissues. Abnormal expression of CD117 may be observed in several hematological malignancies and bone marrow disorders, making it a valuable marker in diagnostic immunophenotyping panels.

Flow cytometry allows rapid identification and quantification of CD117-positive cells by analyzing thousands of cells individually. The test is commonly performed on peripheral blood, bone marrow aspirates, or other suitable specimens as part of the diagnostic workup for leukemia, myelodysplastic syndromes, and related disorders.

Benefits of the Test

• Detects and measures CD117 (KIT) expression
• Assists in leukemia diagnosis and classification
• Supports immunophenotyping of bone marrow disorders
• Helps identify abnormal cell populations
• Assists hematologists in treatment planning
• Provides valuable diagnostic and prognostic information

Why Doctors Recommend This Test

Doctors may recommend Flow Cytometry CD117 testing for:

• Suspected acute leukemia
• Acute Myeloid Leukemia (AML) evaluation
• Myelodysplastic syndrome assessment
• Bone marrow disorder investigation
• Hematological malignancy workup
• Monitoring abnormal blast cell populations
• Follow-up of known blood cancers
• Comprehensive immunophenotyping panels

The test is generally interpreted as part of a broader flow cytometry panel rather than as a standalone marker.

Preparation Before Test

The test requires a suitable specimen such as:

• Peripheral blood
• Bone marrow aspirate
• Other clinically appropriate samples

Preparation may include:

• No fasting is usually required
• Inform your doctor about current treatments
• Follow sample collection instructions provided by the laboratory

The procedure involves standard sample collection and laboratory analysis.

Normal Reporting Time

Results are generally available within 1 to 3 working days, depending on laboratory workflow and the complexity of the immunophenotyping panel.

Who Should Take This Test?

• Patients with suspected leukemia
• Individuals with abnormal blood counts
• Patients undergoing bone marrow evaluation
• Individuals with suspected myelodysplastic syndromes
• Patients requiring immunophenotyping studies
• Individuals referred by hematologists or oncologists

Flow Cytometry CD117 testing is an important component of modern hematology diagnostics and contributes to accurate disease classification.

Clinical Significance

CD117 expression may be observed in:

• Acute Myeloid Leukemia (AML)
• Myelodysplastic Syndromes (MDS)
• Mast Cell Disorders
• Hematopoietic Stem and Progenitor Cells
• Certain Myeloproliferative Disorders
• Other Hematological Malignancies

The interpretation of CD117 expression is always performed alongside additional flow cytometry markers and clinical findings to establish an accurate diagnosis.

Important Note

CD117 testing is typically included within a multiparameter flow cytometry panel and should not be interpreted in isolation. Comprehensive evaluation by a hematologist is essential for accurate clinical interpretation.